Eli Lilly to Invest $27 Billion in New U.S. Manufacturing

Eli Lilly to Invest $27 Billion in US Manufacturing Sites, Ties Move to Trump’s Policies

Eli Lilly said it will invest at least $27 billion to build four new manufacturing sites in the U.S., as demand for its blockbuster weight loss and diabetes injections soars and the company develops new drugs for other conditions.

The announcement comes as drugmakers and companies across different industries work to build goodwill with President Donald Trump, who has emphasized reshoring manufacturing to the U.S. and reducing reliance on foreign supply chains. He has threatened companies — and pharmaceutical businesses in particular — with tariffs if they do not manufacture products in the U.S.

The company made the announcement at an event in Washington, D.C., emphasizing the political undertones of the strategy. The event featured several speakers from the Trump administration, including Kevin Hassett, director of the White House National Economic Council, and Commerce Secretary Howard Lutnick, who explicitly tied the announcement to Trump’s policies.

The Largest Pharmaceutical Expansion Investment in U.S. History

The move brings Eli Lilly’s total U.S. manufacturing investments to more than $50 billion in recent years. The company’s CEO, David Ricks, called the investment "the largest pharmaceutical expansion investment in U.S. history." The new sites will create more than 3,000 jobs for workers such as engineers and scientists, along with 10,000 construction jobs as the plants are built.

Future Sites and Pipeline

Eli Lilly has not decided on the location of the four new U.S. sites, but will be accepting location submissions through March 13 and will announce decisions on new sites in the coming months. The company is optimistic about its pipeline across therapeutic areas, including cardiometabolic health, oncology, immunology, and neuroscience.

The new investments build on the success of Zepbound and Mounjaro, which share dominance of the booming market for so-called GLP-1 drugs with Novo Nordisk’s weight loss drug Wegovy and diabetes treatment Ozempic.

Counterfeit and Compounded Medications

Ricks took a shot at cheaper compounded versions of its injectable drugs, saying "America faces a growing threat from an influx of counterfeit and compounded medications." The company’s efforts to boost the supply of Zepbound and Mounjaro aim to ensure that eligible patients are safely accessing those branded treatments instead of cheaper compounded versions.

Conclusion

Eli Lilly’s $27 billion investment in the U.S. aims to address the growing demand for its blockbuster weight loss and diabetes injections, while also aligning with President Trump’s policies on reshoring manufacturing and reducing reliance on foreign supply chains. The company’s efforts to boost the supply of Zepbound and Mounjaro will ensure that eligible patients are safely accessing those branded treatments instead of cheaper compounded versions.

Frequently Asked Questions

Q: What is the total investment by Eli Lilly in the U.S. manufacturing sites?
A: The company’s total U.S. manufacturing investments are more than $50 billion in recent years.

Q: How many jobs will be created by the new manufacturing sites?
A: The new sites will create more than 3,000 jobs for workers such as engineers and scientists, along with 10,000 construction jobs as the plants are built.

Q: What are the locations of the new U.S. manufacturing sites?
A: Eli Lilly has not yet decided on the locations of the four new U.S. sites, but will be accepting location submissions through March 13 and will announce decisions on new sites in the coming months.